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oward J. Eisen, MD, Shelley R. Hankins, MD
hiladelphia, Pennsylvania
ardiac transplantation provides definitive management of
evere heart failure in selected patients who have exhausted
ll other options. The results of transplantation have im-
roved steadily as a result of improved immunosuppressive
trategies, and advances in the therapy of post-transplant
omplications, such as infections and rejection, and in
ntensive care unit management (1,2). A severe donor
hortage has limited the availability of donor hearts, result-
ng in prolonged waits for organs for patients with advanced
eart failure and tenuous hemodynamics. This necessitated
he development of left ventricular assist devices (LVADs)
s bridges to transplantation to provide mechanical circula-
ory support for patients whose heart failure was refractory
See page 312
o other therapies, including inotropes (3). These devices are
pproved by the Food and Drug Administration (FDA) and
re widely used. The first LVADs were pulsatile flow
evices with an internal volume-displacement mechanism
or pumping blood, powered by pneumatic or electric
ources, and inflow and outflow valves. In many ways, these
evices mimic the native circulatory systems that they were
mplanted to support with distinct periods of systole and
iastole (4–6). LVADs improved survival in patients wait-
ng for cardiac transplantation (3).
With 500,000 new cases of congestive heart failure
iagnosed annually, cardiac transplantation remains an op-
ion for only a small fraction of these patients. By some
stimates, as many as 200,000 patients who are not candi-
ates for transplants would potentially benefit from me-
hanical circulatory support (7,8). This was the rationale for
he REMATCH (Randomized Evaluation of Mechanical
Editorials published in the Journal of the American College of Cardiology reflect the
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From the Division of Cardiology, Drexel University College of Medicine and
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n the Thoratec HeartMate II Destination Therapy Study. Dr. Hankins is a sub-PI
n the current Thoratec HMII Destination Trial.ssistance for the Treatment of Congestive Heart Failure)
rial, which ushered in the era of destination therapy (9).
his study demonstrated a significant improvement in survival
or patients receiving pulsatile flow LVADs (Thoratec
eartMate, Thoratec Corporation, Pleasanton, California)
ompared with optimal medical therapy, which generally
eant inotropic support. Improvements in functional class
nd quality of life were also noted.
Yet, the REMATCH trial also revealed the limitations of
sing pulsatile flow devices for long-term mechanical circu-
atory support. The 1-year survival for LVAD patients was
nly 52%, and device failure was frequent (9). Patients
eceiving LVADs also succumbed to device-related infec-
ions that were difficult to manage without device replace-
ent. Of patients surviving 2 years with the pulsatile
evices, 65% required replacement (10). The pulsatile de-
ices’ large size also limited their use to larger patients. As
result of these limitations, the adoption of destination
herapy for patients with refractory advanced heart failure
ho are not transplant candidates has been slow at best.
Several continuous flow pumps entered clinical trials
ithin the past few years. These devices offered the poten-
ial advantages of smaller size, less extensive surgical proce-
ures for implantation, and the rotary, continuous flow
esign that would improve durability and reduce the likeli-
ood of device breakdown and malfunction (11–13). An
nitial experience of 133 patients receiving the HeartMate II
ontinuous flow rotary pump LVAD as a bridge to trans-
lant demonstrated a 75% 6-month and 68% 12-month
urvival with a significant improvement in functional class,
-min walk test results, and quality of life (14). Complica-
ions included stroke, post-operative bleeding, right ven-
ricular failure, percutaneous lead infection, and device
hrombosis.
In this issue of the Journal, Pagani et al. (15) report the
utcomes of 281 patients who have reached study end point
r completed 18 months of post-operative follow-up in this
ridge to transplant trial (ClinicalTrials.gov number
CT00121472). Patients at 33 centers in the U.S. who
ere waiting for cardiac transplantation and were United
etwork of Organ Sharing status 1A or 1B were enrolled
ith the HeartMate II LVAD implanted. Post-operative
edical care was center specific. The primary end point was
he percentage of patients who had received a cardiac
ransplant, had the LVAD explanted because of recovery of
ardiac function, or who continued to have mechanical
upport with the LVAD at 18 months. The 281 patients
ncluded 18 months of follow-up for the original 133
atients reported previously (14). The population enrolled
as particularly ill because a majority was receiving inotro-
ic support, one third was supported by at least 2 inotropes,
nd 45% had intra-aortic balloon pump support.
At 18 months, 222 patients (79%) reached the primary
nd point of receiving a transplant, having the device
xplanted for cardiac recovery or ongoing mechanical circu-
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July 21, 2009:322–4 Mechanical Circulatory Support 2.0atory support. Of these, 157 (56%) had undergone trans-
lant, 58 (20.6%) were alive with LVAD support, 56 (20%)
ad died, and 7 (2.5%) had the device explanted for cardiac
ecovery. The median duration for mechanical support for
ll patients was 155 days. Overall patient survival with
VAD support was 82% at 6 months, 73% at 12 months,
nd 72% at 18 months. Major causes of death included
epsis (4%), stroke (4%), right ventricular failure (3%),
evice-related deaths (3%), and multiorgan failure (2%).
ost of the deaths (77%) occurred within the first 6
ost-operative months. Adverse events were frequent and
ncluded strokes (8.9%), localized device-related infections
30%), percutaneous lead infections (14%), and right ven-
ricular failure (19%), most of whom needed inotropic
upport for at least 14 days. Most patients (59%) had at least
post-operative surgical procedure. Functional class, 6-min
alk test, and quality of life were all significantly improved
fter 6 months of LVAD support compared with the
re-LVAD baseline. Hemodynamic support provided by
he continuous flow LVADs was similar to that of pulsatile
ow devices.
The study results suggest that comparable hemodynamic
upport and improvements in functional class, 6-min walk
est results, and quality of life can be achieved with the
ontinuous flow LVADs compared with the pulsatile flow
evices but with improved survival compared to historical
ontrols using the older LVADs (3,6,16,17). Adverse
vents, including infection, post-operative bleeding, right
entricular failure requiring right ventricular assist device
upport, and nonstroke neurological events were signifi-
antly less frequent with the continuous flow than the
ulsatile flow LVADs when compared with historical con-
rol patients (3). There also were no mechanical failures
elated to the pumping mechanism in the continuous flow
VADs, although 11 patients required a pump exchange as
he result of device thrombosis, infection, percutaneous lead
racture, or complications at the time of implantation.
hese results suggest that continuous-flow devices may not
nly provide more reliable methods of mechanical support
or patients awaiting cardiac transplantation but may do this
ith fewer complications of infection and device failure.
Although the present study only involved the use of
VADs as bridges to transplant, the implications for
estination therapy are apparent. Patients receiving LVADs
ermanently for mechanical support are even more in need
f devices that are durable, less likely to fail, and less prone
o infection as they have no backup therapy such as
ransplantation. The results of this study would at least
rovide preliminary evidence that continuous flow devices
ave advantages that would be appealing in patients receiv-
ng mechanical support for destination therapy.
There are limitations to this study, of which the most
ignificant is the absence of randomization with a pulsatile
ow LVAD approved by the FDA for bridge to transplant
such as the HeartMate LVAS) as a comparator. The results
howing the superiority of the continuous flow devicesompared with pulsatile devices using historic controls in
tudies ranging over a 10-year period (3,6,16,17). Compar-
son with the overall survival in the REMATCH trial may
lso not be entirely valid because the 52% annual survival in
he LVAD group was for all comers and the REMATCH
opulation by design included patients who were not
ransplant candidates (9).
However, there was a “learning curve” within theREMATCH
tudy, with patients receiving LVADs later in the trial
aving better survival. This has also been observed in
ingle-center results of destination therapy with pulsatile
VADs (18). Though the 18-month mortality in this
ohort was 20%, rehospitalizations and surgical operations
ere still frequent occurrences in the present bridge-to-
ransplant study. Optimization of patient selection by use of
ecently published risk assessment scores may help reduce
dverse events (19,20). Ultimately, the utility of continuous
ow LVADs for destination therapy will be defined by
he ongoing randomized trial comparing the HeartMate II
o the HeartMate LVAS, which is the FDA approved
evice for destination therapy (ClinicalTrials.gov number
CT00121485).
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